These findings challenge not only the earlier report by Kasitinon et al. (2019), claiming that TRPML1-deficient melanoma cells exhibit decreased survival, proliferation, and tumor growth [15,16,41,42,43], but also several other reports on the role of TRPML1 in cancer, either claiming that cancer cells are vulnerable to TRPML1 inhibition or downregulation [41,44,45,46]. This evidence concerns the gene MCOLN1 and cancer.